4//SEC Filing
Larson Yi 4
Accession 0001209191-21-007037
CIK 0001595893other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 9:47 PM ET
Size
29.0 KB
Accession
0001209191-21-007037
Insider Transaction Report
Form 4
Larson Yi
EVP & Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-01$54.03/sh+15,702$848,379→ 18,406 total - Sale
Common Stock
2021-02-01$122.94/sh−4,783$588,022→ 13,623 total - Sale
Common Stock
2021-02-01$124.60/sh−2,143$267,018→ 2,904 total - Exercise/Conversion
Common Stock
2021-02-02$54.03/sh+14,298$772,521→ 17,002 total - Sale
Common Stock
2021-02-02$128.41/sh−400$51,364→ 15,602 total - Exercise/Conversion
Stock Option (right to buy)
2021-02-02−14,298→ 282,397 totalExercise: $54.03Exp: 2029-08-25→ Common Stock (14,298 underlying) - Sale
Common Stock
2021-02-02$129.80/sh−4,574$593,705→ 11,028 total - Sale
Common Stock
2021-02-02$131.73/sh−1,057$139,239→ 2,704 total - Sale
Common Stock
2021-02-01$123.70/sh−8,576$1,060,851→ 5,047 total - Sale
Common Stock
2021-02-01$126.07/sh−200$25,214→ 2,704 total - Sale
Common Stock
2021-02-02$127.58/sh−1,000$127,580→ 16,002 total - Sale
Common Stock
2021-02-02$130.58/sh−7,267$948,925→ 3,761 total - Exercise/Conversion
Stock Option (right to buy)
2021-02-01−15,702→ 296,695 totalExercise: $54.03Exp: 2029-08-25→ Common Stock (15,702 underlying)
Footnotes (12)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 20, 2020.
- [F10]The weighted average sale price for the transaction reported was $130.58, and the range of prices were between $130.25 and $131.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F11]The weighted average sale price for the transaction reported was $131.73, and the range of prices were between $131.38 and $132.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F12]25% of the shares vested on August 26, 2020 with the remaining shares vesting in equal monthly installments over the following three years thereafter.
- [F2]The Reporting Person acquired 86 shares on June 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 396 shares on December 10, 2020 pursuant the ESPP.
- [F3]The weighted average sale price for the transaction reported was $122.94, and the range of prices were between $122.28 and $123.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $123.70, and the range of prices were between $123.29 and $124.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $124.60, and the range of prices were between $124.34 and $125.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The weighted average sale price for the transaction reported was $126.07, and the range of prices were between $125.58 and $126.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F7]The weighted average sale price for the transaction reported was $127.58, and the range of prices were between $127.00 and $127.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F8]The weighted average sale price for the transaction reported was $128.41, and the range of prices were between $128.12 and $128.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F9]The weighted average sale price for the transaction reported was $129.80, and the range of prices were between $129.215 and $130.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Turning Point Therapeutics, Inc.
CIK 0001595893
Entity typeother
Related Parties
1- filerCIK 0001785987
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 9:47 PM ET
- Size
- 29.0 KB